Search details
1.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Article
in English
| MEDLINE | ID: mdl-38657201
2.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Article
in English
| MEDLINE | ID: mdl-35661166
3.
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cancer
; 130(6): 886-900, 2024 03 15.
Article
in English
| MEDLINE | ID: mdl-37960969
4.
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Cancer
; 129(13): 2035-2046, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36991547
5.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-37132225
6.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Article
in English
| MEDLINE | ID: mdl-34388396
7.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Article
in English
| MEDLINE | ID: mdl-34175021
8.
Eomesodermin driven IL-10 production in effector CD8+ T cells promotes a memory phenotype.
Cell Immunol
; 335: 93-102, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30528350
9.
mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation.
J Immunol
; 198(10): 3939-3948, 2017 05 15.
Article
in English
| MEDLINE | ID: mdl-28424242
10.
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.
Semin Oncol Nurs
; 40(3): 151621, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38600011
11.
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.
CPT Pharmacometrics Syst Pharmacol
; 2024 Jun 03.
Article
in English
| MEDLINE | ID: mdl-38831634
12.
Teclistamab: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(1): e13717, 2024 01.
Article
in English
| MEDLINE | ID: mdl-38266057
13.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Blood Adv
; 8(1): 194-206, 2024 01 09.
Article
in English
| MEDLINE | ID: mdl-38052042
14.
Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.
J Exp Med
; 204(9): 2015-21, 2007 Sep 03.
Article
in English
| MEDLINE | ID: mdl-17698591
15.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 39(1): 81-89, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36271807
16.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
J Clin Oncol
; 41(6): 1265-1274, 2023 02 20.
Article
in English
| MEDLINE | ID: mdl-35658469
17.
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Target Oncol
; 18(5): 667-684, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37713090
18.
Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche.
J Immunol
; 185(9): 4988-92, 2010 Nov 01.
Article
in English
| MEDLINE | ID: mdl-20935204
19.
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
Target Oncol
; 17(4): 433-439, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35749004
20.
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): 690-701, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35764490